Turn Therapeutics Inc. - Common Stock (TTRX)

Turn Therapeutics (NASDAQ:TTRX) outlined the final stage two design and data-driven expansion of its GX-03 phase II program in atopic dermatitis during an investor update call, saying the revised approach was informed by an interim analysis of the first 50 completers in the ongoing trial. Brad Burn

U.S. stock futures fell on Thursday following Wednesday’s mixed close. Futures of major benchmark indices were lower.

Stock futures mixed, investor focus on PepsiCo, Costco, and Delta earnings. Turn Therapeutics surges, while Levi Strauss reports after bell.